Despite previous reports have suggested that MYCN-amplification may render neuroblastoma cells sensitive to p53–MDM2 PPIs [16, 17], little is known about the mechanistic details and whether other factors may serve as biomarker to predict the therapeutic responses to those PPIs, especially in cancers without MYCN-amplification. The gene discussed is TP53; the disease is cancer.